Empagliflozin inhibits coronary microvascular dysfunction and reduces cardiac pericyte loss in db/db mice

BACKGROUND: Coronary microvascular dysfunction (CMD) is a pathophysiological feature of diabetic heart disease. However, whether sodium-glucose cotransporter 2 (SGLT2) inhibitors protect the cardiovascular system by alleviating CMD is not known. OBJECTIVE: We observed the protective effects of empag...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Yimin, Li, Qing, Zhou, Yuanchen, Ye, Zixiang, Wu, Chao, Xie, Enmin, Li, Yike, Li, Peizhao, Wu, Yaxin, Guo, Ziyu, Yu, Changan, Zheng, Jingang, Gao, Yanxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800791/
https://www.ncbi.nlm.nih.gov/pubmed/36588571
http://dx.doi.org/10.3389/fcvm.2022.995216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800791/
https://www.ncbi.nlm.nih.gov/pubmed/36588571
http://dx.doi.org/10.3389/fcvm.2022.995216

Ejemplares similares